Abstract
Gestational diabetes mellitus (GDM) is a common pregnancy complication. Recent epidemiological data have shown that GDM prevalence has been on the increase worldwide. GDM could lead to adverse pregnancy outcomes and is usually associated with higher costs for its treatment and management. Pharmacoeconomics has become a crucial component of the healthcare systems in recent years because of the steadily rising costs. Despite this, there are few pharmacoeconomic studies evaluating the expenses of pregnancies impacted by GDM.
This article presents a brief introduction to pharmacoeconomics and provides awareness of the economic impact of GDM. Studies associated with health care costs of GDM were reviewed and an attempt was made to determine its global economic burden.
Reference38 articles.
1. 1. Todorova K, Dimitrova Z, Stefanova M, et al. [Pharmacoeconomic analysis of diabetes treatment during pregnancy.] Pharmacia 2008; 55(1-4):56–60 [Bulgarian].
2. 2. Cavassini AC, Lima SA, Calderon IM, et al. Cost-benefit of hospitalization compared with outpatient care for pregnant women with pregestational and gestational diabetes or with mild hyperglycemia, in Brazil. Sao Paulo Med J 2012; 130(1):17–26.
3. 3. Brandle M, Herman W. Cost analysis of diabetes and pregnancy. In: Hod M, Jovanovic L, Di Renzo GC, Leiva A, Langer O, editors. Textbook of diabetes and pregnancy. London: Martin Dunitz; 2003:529–38.
4. 4. Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management and care. Int J Gynecol Obstet 2015; 131(Suppl. 3):173–211.
5. 5. Hod M, Yogev Y. Goals of metabolic management of gestational diabetes: is it all about the sugar? Diabetes Care 2007; 30 Suppl 2:S180–7.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献